CD8A and breast carcinoma: Our results further confirmed that CD8+ T cells are the key effector cell population and have positive effects on anti-tumor immunity and patient clinical outcomes, and that CD4+ and CD8+ T cells have opposing prognostic effects for breast cancer patient outcomes.